Hyku Biosciences develops small molecule therapeutics that utilize precise covalent targeting to inactivate disease-causing proteins, focusing on non-cysteine amino acid binding. This approach addresses challenges in selectivity and druggability, enhancing the efficacy of treatments for various diseases.
Funding
$64M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-causing proteins are difficult to target effectively with traditional drugs due to challenges in selectivity, druggability, and the development of resistance. Conventional treatments may lack the precision needed to interact with these proteins in a way that maximizes therapeutic benefit while minimizing off-target effects.
Solution
Hyku Biosciences is developing small molecule therapeutics that utilize a precise covalent targeting strategy to inactivate disease-causing proteins. The company's proprietary Hyku platform identifies compounds that covalently bind to non-cysteine amino acids on target proteins. This approach facilitates the development of novel therapies that can overcome challenges associated with many disease targets, including selectivity, druggability, and resistance. By expanding the boundaries of drug discovery, Hyku aims to transform conventional treatment paradigms and improve patient outcomes.
Target Audience
The primary target audience includes patients suffering from diseases driven by difficult-to-target proteins, as well as pharmaceutical companies seeking innovative therapeutic approaches.
Features
- Proprietary Hyku platform for identifying compounds that covalently bind non-cysteine amino acids
- Focus on developing small molecule therapeutics with novel mechanisms of action
- Precise covalent targeting to inactivate disease-causing proteins
- Enhanced selectivity and druggability compared to traditional approaches
- Potential to address drug resistance mechanisms